Patents
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
03/2004
03/31/2004EP1402262A2 MAP3Ks AS MODIFIER OF THE p53 PATHWAY AND METHODS OF USE
03/31/2004EP1402260A2 Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
03/31/2004EP1402256A2 P-cadherin as a target for anti-cancer therapy
03/31/2004EP1402075A1 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
03/31/2004EP1402067A2 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE
03/31/2004EP1402066A2 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
03/31/2004EP1402064A2 Protein arrays and methods and systems for producing the same
03/31/2004EP1402058A2 Dgks as modifiers of the p53 pathway and methods of use
03/31/2004EP1402054A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
03/31/2004EP1402053A2 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
03/31/2004EP1402051A2 Lces as modifiers of the p53 pathway and methods of use
03/31/2004EP1402039A1 MUTANT FORMS OF EtxB AND CtxB AND THEIR USE AS CARRIERS
03/31/2004EP1402031A2 Atopy
03/31/2004EP1402030A2 43238, a g protein-coupled receptor and uses therefor
03/31/2004EP1402019A1 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes
03/31/2004EP1402015A2 A soluble complex comprising a retroviral surface glycoprotein
03/31/2004EP1402000A2 Structural and cytoskeleton-associated proteins
03/31/2004EP1401918A2 Biodegradable poly(beta-amino esters) and uses thereof
03/31/2004EP1401872A1 Antigen targeting
03/31/2004EP1401871A1 Immunological binding molecules inhibiting the syncytial fusion of trophoblast cells
03/31/2004EP1401870A2 Antibodies against tumor necrosis factor delta (april)
03/31/2004EP1401869A1 Molecules and methods for inhibiting shedding of kim-1
03/31/2004EP1401867A2 Mycobacterial antigens expressed under low oxygen tension
03/31/2004EP1401866A2 Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
03/31/2004EP1401865A2 Pathogenic and commensal vaccine antigens
03/31/2004EP1401861A2 Cads as modifiers of the p53 pathway and methods of use
03/31/2004EP1401859A2 Chimeric flavivirus vectors
03/31/2004EP1401858A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/31/2004EP1401855A2 Novel fibroblast growth factor and nucleic acids encoding same
03/31/2004EP1401849A1 Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes
03/31/2004EP1401498A1 Anti-ngf antibodies for the treatment of various disorders
03/31/2004EP1401496A1 Compositions and methods for treating hyperimmune response in the eye
03/31/2004EP1401493A1 Subunit vaccines and processes for the production thereof
03/31/2004EP1401492A1 Ltb4 as vaccine adjuvant
03/31/2004EP1401491A1 Methods for inducing an immune response with an elevated th1/th2 ratio, by intracellular induction of nfkappab
03/31/2004EP1401489A2 Capsular polysaccharide solubilisation and combination vaccines
03/31/2004EP1401488A1 Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
03/31/2004EP1401486A2 Novel human proteins, polynucleotides encoding them and methods of using the same
03/31/2004EP1401479A2 Detection and therapy of vulnerable plaque with photodynamic compounds
03/31/2004EP1401476A2 Igf antagonist peptides
03/31/2004EP1401475A2 Prmts as modifiers of the p53 pathway and methods of use
03/31/2004EP1401472A2 Alternative splice forms of proteins as basis for multiple therapeutic modalities
03/31/2004EP1401470A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
03/31/2004EP1401443A1 Novel anti-infectives
03/31/2004EP1401410A2 Immunomodulation and effect on cell processes relating to serotonin family receptors
03/31/2004EP1401377A2 Methods for treating cancer
03/31/2004EP1401281A2 Toll/interleukin-1 receptor adaptor protein (tirap)
03/31/2004EP1401269A2 Transgenic animal model of bone mass modulation
03/31/2004EP1181318B1 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
03/31/2004EP1015560B1 Modified small rna viruses
03/31/2004EP0877624B1 Streptococcal c5a peptidase vaccine
03/31/2004EP0858343B1 Continuous low-dose cytokine infusion therapy
03/31/2004EP0784677B1 Inhibitor of stem cell proliferation and uses thereof
03/31/2004EP0656948B1 Bordetella bronchiseptica vaccine
03/31/2004CN1486206A Methods and vaccines for providing in ovo protection against turkey rhinotracheitis
03/31/2004CN1486194A Colorstrum-based composition
03/31/2004CN1486192A Binding domain-immunoglobulin fusion proteins
03/31/2004CN1486191A Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
03/31/2004CN1485343A Production method of specific IgY for venereal disease and its combined preparation
03/31/2004CN1485095A Preparation process of the freeze drying protective agent for the vaccin used for animals
03/31/2004CN1484972A Anti-diarrhea yelk antibody feed additive for swine and injection formulation, and preparation method
03/31/2004CN1143679C Method and material for treating and preventing mucosal tissue inflammation
03/30/2004US6713617 Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens
03/30/2004US6713450 Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid β for induction of an immune response to amyloid β and amyloid deposits
03/30/2004US6713301 Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
03/30/2004US6713296 Due to a deletion of at least 10 amino acids, neurovirulence is attenuated as compared to a naturally occurring varicella-zoster virus
03/30/2004US6713291 Method of immunotherapy; obtain electrodes, obtain waveform generator, generate electrically conductive pathways between electrodes and generator, incubate with transfer particles, transfer particles into cells with electrical pulse
03/30/2004US6713286 Purified fiv-141 virus; vaccines
03/30/2004US6713282 End selection in directed evolution
03/30/2004US6713279 Targeting of a genetic vaccine to a particular tissue or cell type of interest by creating a library of mutant polypeptides and screening them against cell of interest
03/30/2004US6713266 Immunoassay method for measuring a cyclosporine and its metabolites
03/30/2004US6713073 Whole body spray
03/30/2004US6713072 Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
03/30/2004US6713071 Proteins from actinobacillus pleuropneumoniae
03/30/2004US6713069 Compositions and methods for detecting, preventing, and treating African Hemorrhagic Fever
03/30/2004US6713068 Live recombined vaccines injected with adjuvant
03/30/2004US6713066 Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
03/30/2004US6713064 Immune enhancing agent for treating HIV infected humans
03/30/2004US6713059 Antibodies raised against immunogenic conjugates of gram-negative bacterial autoinducer molecules
03/30/2004US6713056 Combined preparation for the treatment of neoplasic diseases or of infectious diseases
03/30/2004CA2277165C Purification and/or concentration of dna by cross-flow filtration, separation of endotoxins from a nucleic acid preparation
03/30/2004CA2235471C Dna encoding a plasminogen activating protein
03/30/2004CA2136103C Antibiotic cryptdin peptides and methods of their use
03/25/2004WO2004025416A2 Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby
03/25/2004WO2004025267A2 Method for testing drug susceptibility of hiv
03/25/2004WO2004025263A2 Protein and peptide expression for passive immunity
03/25/2004WO2004025256A2 Viral deconstruction through capsid assembly in vitro
03/25/2004WO2004024952A1 Method of diagnosing ovarian endometriosis
03/25/2004WO2004024937A2 Virulence-associated nucleic acids and proteins and uses thereof
03/25/2004WO2004024920A1 Preventives/remedies for neurodegenerative diseases
03/25/2004WO2004024909A2 Recombinant colstridium neurotoxin fragments
03/25/2004WO2004024904A2 Infectious hepacivirus pseudo-particles containing functional e1, e2 envelope proteins
03/25/2004WO2004024902A1 A method of treating an autoimmune disease
03/25/2004WO2004024900A1 USE OF DENDRITIC CELLS (DCs) EXPRESSING INTERLEUKIN 12 (IL-12)
03/25/2004WO2004024889A2 Production of bispecific molecules using polyethylene glycol linkers
03/25/2004WO2004024884A2 Syts as modifiers of the p21 pathway and methods of use
03/25/2004WO2004024883A2 PAKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE
03/25/2004WO2004024882A2 FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
03/25/2004WO2004024880A2 AMPDs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
03/25/2004WO2004024879A2 RORs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE